Download Bengt Wretlind

Bengt Wretlind
Curriculum vitae (2013)
Born:
January 5, 1940
Social status:
Married, two sons (born 1973 and 1976).
Present position: Professor and Chief Physician, Division of Clinical Bacteriology, Huddinge
University Hospital
Education:
Graduation from college 1958.
1967, MD, Karolinska Institutet
1974, Specialist in clinical bacteriology
1977, PhD, Karolinska Institutet
1978, Associate Professor, Karolinska Institutet
2000, Professor, Karolinska Institutet
Positions:
Last position
1967 - 1969, Physician, Department of Infectious Diseases, Roslagstull Hosp,
Stockholm, Sweden
1969 - 1978, Physician, Department of Clinical Microbiology, Karolinska
Hospital, Stockholm
1978 Associate Professor, Karolinska Institutet
1979 Postdoctoral position: Research Associateship, Naval Medical Research
Institute, Bethesda, Maryland, USA
1980, Physician, Department of Clinical Microbiology, Karolinska Hospital,
Stockholm
1981-1984, Chief Physician and Acting Professor, Department of Clinical
Microbiology, Karolinska Institutet at Karolinska Hospital, Stockholm
1985 - 1993, Chief Physician and Head of Department, Department of Clinical
Bacteriology, Danderyd Hospital, Danderyd, Sweden
1994 - 1995, Acting Professor and Chief Physician, Division of Clinical
Bacteriology, Karolinska Institutet at Huddinge University Hospital.
1996, Chief Physician and Head of Department, Department of Clinical
Bacteriology, Danderyd Hospital, Danderyd.
1997, Chief Physician, Department of Clinical Microbiology, Karolinska
Hospital
1998, Senior Lecturer and Chief Physician, Department Laboratory Medicine,
Division of Clinical Bacteriology, Karolinska Institutet at Huddinge University
Hospital.
2000, April, Professor in Clinical Bacteriology and Chief Physician, Karolinska
Institutet at Huddinge University Hospital
2006 April 1, Professor emeritus
Tutoring
Principal supervisor for 9 PhD students:
Laila Elsheikh, 1986
Annelie Brauner 1987
Gunnar Granström 1989
Shah Jalal 2000
John Danin 2003
Nagwa El Amin 2003
Emma Lindbäck 2006
Christian Giske 2007
Sohidul Islam 2008
Assistant supervisor for 11 PhD students
Publications:
PhD thesis 1977: Role of proteases in the pathogenicity of Pseudomonas
aeruginosa.
169 papers on various aspects of clinical bacteriology, especially pathogenicity,
genetics and drug resistance mechanisms of Pseudomonas aeruginosa; and
immune response in infectious diseases. About 100 abstracts from conferences
and meetings.
ORIGINAL ARTICLES
1.
Wretlind, B; Möllby, R; Wadström, T. Separation of two hemolysins from Aeromonas hydrophila by
isoelectric focusing. Infection and Immunity 4:503-505, 1971.
2.
Wretlind, B; Hedén, L; Wadström, T. Formation of extracellular haemolysin by Aeromonas hydrophila in
relation to protease and staphylolytic enzyme. Journal of General Microbiology 78:57-65, 1973.
3.
Wretlind, B; Hedén, L; Sjöberg, L; Wadström, T. Production of enzymes and toxins by hospital strains of
Pseudomonas aeruginosa in relation to serotype and phage-typing pattern. Journal of Medical Microbiology
6:91-100, 1973.
4.
Lagercrantz, R; Nyström, B; Wretlind, B. Staphylococci and infection in maternity wards. IV. Studies on a
partial rooming-in system. Acta Paediatrica Scandinavica 62:621-624, 1973.
5.
Wretlind, B; Nord, C-E; Wadström, T. In vitro sensitivity of isolates of Pseudomonas aeruginosa to
carbenicillin, gentamicin, tobramycin, and some other antibiotics. Scandinavian Journal of Infectious
Diseases 6:49-52, 1974.
6.
Wadström, T; Söderlind, O; Möllby, R; Wretlind, B. Release of heat-labile enterotoxin from cells of E.
coli strain 853/67. IRCS (Research on: Biochemistry; Biophysics; Microbiology) 2:1312, 1974.
7.
Wadström, T; Möllby, R; Jeansson, S; Wretlind, B. Biological studies on Ampholine carrier ampholytes.
Science Tools 21:2-4, 1974.
8.
Nord, C-E; Wadström, T; Wretlind, B. Sensitivity of different Pseudomonas species and Aeromonas
hydrophila to trimethoprim and sulfamethoxazole separately and in combination. Medical Microbiology and
Immunology 160:1-7, 1974.
9.
Nord, C-E; Wadström, T; Wretlind, B. Synergistic effect of combinations of sulfamethoxazole,
trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia. Antimicrobial
Agents and Chemotherapy 6:521-523, 1974.
10.
Wretlind, B; Goertz, G; Illéni, T; Lundell, S; Seger, B. Antibiotic sensitivity testing by zone-scanning of
agar strips (a preliminary report). In: Automation in Microbiology and Immunology, pp. 293-304. Edited by
C-G Hedén and T. Illéni. John Wiley & Sons, New York, 1975.
11.
Eneroth, CM; Lundberg, C; Wretlind, B. Antibiotic concentration in maxillary sinus secretion and in the
sinus mucosa. Chemotherapy 21 (Suppl. 1):1-7, 1975.
12.
Nord, C-E; Sjöberg, L; Wadström, T; Wretlind, B. Characterization of three Aeromonas and nine
Pseudomonas species by extracellular enzymes and haemolysins. Medical Microbiology and Immunology
161:79-87, 1975.
13.
Nord, C-E; Wadström, T; Wretlind, B. Antibiotic sensitivity of two Aeromonas and nine Pseudomonas
species. Medical Microbiology and Immunology 161:89-97, 1975.
14.
Nord, C-E; Wadström, T; Dornbusch, K; Wretlind, B. Extracellular proteins in five clostridial species
from human infections. Medical Microbiology and Immunology 161:145-154, 1975.
15.
Carenfelt, C; Eneroth, C-M; Lundberg, C; Wretlind, B. Evaluation of the antibiotic effect of treatment of
maxillary sinusitis. Scandinavian Journal of Infectious Diseases 7:259-264, 1975.
16.
Palmblad, J; Wretlind, B. Fever and bacterial infections in acute leukemia. Opuscula Medica 21:20-22,
1976.
17.
Wadström, T; Ljungh, Å; Wretlind, B. Enterotoxin, haemolysin and cytolytic protein in Aeromonas
hydrophila from human infections. Acta Pathologica et Microbiologica Scandinavica Section B 84:112-114,
1976.
18.
Wretlind, B; Gezelius, L. Sensitivity of isolates of Pseudomonas aeruginosa to amikacin (BB-K8),
gentamicin, sisomicin and tobramycin. IRCS Medical Science: Microbiology; Pharmacology 4:156, 1976.
19.
Olsson, B; Nord, C-E; Wadström, T; Wretlind, B. Gel electrofocusing combined with zymogram
techniques for the characterization of ß-lactamases from Gram negative bacteria. FEMS Microbiology Letters
1:157- 162, 1977.
20.
Nord, C-E; Wretlind, B; Dahlbäck, A. Evaluation of two test-kits - API and Oxi Ferm tube - for
identification of oxidative-fermentative Gram-negative rods. Medical Microbiology and Immunology 163:9397, 1977.
21.
Wretlind, B; Wadström, T. Purification and properties of a protease with elastase activity from
Pseudomonas aeruginosa. Journal of General Microbiology 103:319-327, 1977.
22.
Wretlind, B; Sjöberg, L; Wadström, T. Protease-deficient mutants of Pseudomonas aeruginosa:
pleiotropic changes in activity of other extracellular enzymes. Journal of General Microbiology 103:329-336,
1977.
23.
Wretlind, B; Kronevi, T. Experimental infections with protease-deficient mutants of Pseudomonas
aeruginosa in mice. Journal of Medical Microbiology 11:145-154, 1978.
24.
Ljungh, Å; Wretlind, B; Wadström, T. Evidence for enterotoxin and two cytolytic toxin in human isolates
of Aeromonas hydrophila. In: Toxins: Animal, Plant and Microbial, pp. 947-960. Edited by P Rosenberg.
Pergamon Press, Oxford and New York, 1978.
25.
Wretlind, B; Gezelius, L; Karlsson, I; Hagberg, R. In vitro activity of a new semisynthetic penicillin, PC904, against ampicillin-resistant Gram-negative bacteria. In: Current Chemotherapy, pp. 638-641. American
Society for Microbiology, Washington, DC, 1978.
26.
Carenfelt, C; Lundberg, C; Nord, C-E; Wretlind, B. Bacteriology of maxillary sinusitis in relation to
quality of the retained secretion. Acta Oto-laryngologica 86:298-302, 1978.
27.
Pavlovskis, OR; Wretlind, B. Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence
factor in experimental mouse burn infection. Infection and Immunity 24:181-187, 1979.
28.
Pavlovskis, OR; Wretlind, B; Hale, ML. The effect of Pseudomonas aeruginosa exotoxin A on antibody
forming mouse spleen cells. In: Natural Toxins, pp. 425-429. Edited by D Eaker and T Wadström. Pergamon
Press, Oxford and New York, 1980.
29.
Reimer, Å; Klementsson, K; Ursing, J; Wretlind, B. The mucociliary activity of the respiratory tract. 1.
Inhibitory effects of products of Pseudomonas aeruginosa on rabbit trachea in vitro. Acta Oto-laryngologica
90:462-469, 1980.
30.
Pavlovskis, OR; Edman, DC; Leppla, SH; Wretlind, B; Lewis, LR; Martin, KE. Protection against
experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.
Infection and Immunity 32:681-689, 1981.
31.
Ljungh, Å; Wretlind, B; Möllby, R. Separation and characterization of enterotoxin and two haemolysins
from Aeromonas hydrophila. Acta Pathologica et Microbiologica Scandinavica Section B 89:387-397, 1981.
32.
Pavlovskis, OR; Yaffe, LJ; Wretlind, B; Galloway, DR. Experimental Pseudomonas aeruginosa infections
in burned mice and rats: description of a model. In: Experimental Bacterial and Parasitic Infections, pp. 103108. Edited by G Keusch and T Wadström. Elsevier, New York, 1983.
33.
Howe, TR; Wretlind, B; Iglewski, BH. Comparison of two methods of genetic exchange in determination
of the genetic locus of the structural gene for Pseudomonas aeruginosa elastase. Journal of Bacteriology
156:58-61, 1983.
34.
Wretlind, B; Pavlovskis, OR. Genetic mapping and characterization of Pseudomonas aeruginosa mutants
defective in the formation of extracellular proteins. Journal of Bacteriology 158:801-808, 1984.
35.
Belfrage, P; Christensen, KK; Christensen, P; Faxelius, G; Feuerberg, Y; Lindén, V; Svenningsen, N;
Wretlind, B. Transient increase of early-onset group B streptococcal septicemia. European Journal of
Obstetrics, Gynecology and Reproductive Biology 17:377-382, 1984.
36.
Granström, M; Ericsson, A; Strandvik, B; Wretlind, B; Pavlovskis, OR; Berka, R; Vasil, ML. Relation
between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients
with cystic fibrosis. Acta Paediatrica Scandinavica 73:772-777, 1984.
37.
Brauner, A; Høiby, N; Kjartansson, J; Kühn, I; Svenberg-Appelgren, P; Wretlind, B. Pseudomonas
cepacia septicemia in patients with burns: report of two cases. Scandinavian Journal of Infectious Diseases
17:63-66, 1985.
38.
Granström, M; Wretlind, B; Markman, B; Pavlovskis, OR; Vasil, ML. Enzyme-linked immunosorbent
assay for detection of antibodies to Pseudomonas aeruginosa exoproteins. European Journal of Clinical
Microbiology 4:197-200, 1985.
39.
Björklind, A; Wretlind, B; Möllegård, I; Schad, PA; Iglewski, BH; Cox, CD. Genetic mapping and
characterization of Pseudomonas aeruginosa mutants that hyperproduce exoproteins. Journal of Bacteriology
162:1329-1331, 1985.
40.
Malmborg, A-S; Alfredsson, H; Strandvik, B; Wretlind, B. Sputum concentrations and clinical effects of
imipenem treatment in patients with cystic fibrosis. Chemiotherapia 4 Supplement:910-911, 1985.
41.
Wretlind, B; Becker, K; Haas, D. Inc P-1 R plasmids decrease the serum resistance and the virulence of
Pseudomonas aeruginosa. Journal of General Microbiology 131:2701-2704, 1985.
42.
Ringertz, S; Eriksson, B; Malmborg, A-S; Nyström, S; Wretlind, B. Use of the antimicrobial removal
device prior to blood culture in patients on antibiotic therapy. European Journal of Clinical Microbiology
4:544-547, 1985.
43.
Brauner, A; Leissner, M; Wretlind, B; Julander, I; Svenson, SB; Källenius, G. Occurrence of Pfimbriated Escherichia coli in patients with bacteremia. European Journal of Clinical Microbiology 4:566569, 1985.
44.
Elsheikh, LE; Abaas, S; Wretlind, B. Adherence of Pseudomonas aeruginosa to tracheal epithelial cells of
mink. Studies on bacterial hydrophobicity and elastase production. Acta Pathologica, Microbiologica et
Immunologica Scandinavica Section B 93:417-422, 1985.
45.
Herngren, L; Broberger, U; Wretlind, B. A simplified model for adjustment of gentamicin in newborn
infants. Acta Paediatrica Scandinavica 75:198-204, 1986.
46.
Elsheikh, LE; Bergman, R; Cryz, Jr, SJ; Wretlind, B. A comparison of different methods for determining
elastase activity of Pseudomonas aeruginosa strains from mink. Acta Pathologica, Microbiologica et
Immunologica Scandinavica Section B 94:135-138, 1986.
47.
Brauner, A; Källenius, G; Wrangsell, G; Wretlind, B; Svenson, SB. Antibody responses to Escherichia
coli J5 lipopolysaccharide and to Salmonella porin in patients with bacteraemia. Microbial Pathogenesis
1:475-481, 1986.
48.
Brauner, A; Källenius, G; Svenson, SB; Wrangsell, G; Wretlind, B. Antibody response to Escherichia
coli J5 lipopolysaccharide in patients with bacteraemia. Microbial Pathogenesis 2:395-396, 1987.
49.
Filloux, A; Murgier, M; Wretlind, B; Lazdunski, A. Characterization of two Pseudomonas aeruginosa
mutants with defective secretion of extracellular proteins and comparison with other mutants. FEMS
Microbiology Letters 40:159-163, 1987.
50.
Elsheikh, LE; Kronevi, T; Wretlind, B; Abaas, S; Iglewski, BH. Assessment of elastase as a
Pseudomonas aeruginosa virulence factor in experimental lung infection in mink. Veterinary Microbiology
13:281-289, 1987.
51.
Lindgren, V; Wretlind, B. Characterization of a Pseudomonas aeruginosa transposon insertion mutant with
defective release of exoenzymes. Journal of General Microbiology 133:675-681, 1987.
52.
Wretlind, B; Björklind, A; Pavlovskis, OR. Role of exotoxin A and elastase in the pathogenicity of
Pseudomonas aeruginosa strain PAO experimental mouse burn infection. Microbial Pathogenesis 2:397-404,
1987.
53.
Örtqvist, Å; Ransjö, U; Wretlind, B. Plasmid analysis as an epidemiological tool in neurosurgical
infections with coagulase negative staphylococci. Epidemiology and Infection 98:231-239, 1987.
54.
Brauner, A; Boefgras, JM; Jacobson, SH; Kaijser, B; Källenius, G; Svenson, SB; Wretlind, B. The use
of biochemical markers, serotype and fimbriation in the detection of Escherichia coli clones. Journal of
General Microbiology, 133:2825-2834, 1987.
55.
Ericsson Hollsing, A; Granström, M; Vasil, ML; Wretlind, B; Strandvik, B. Prospective study of serum
antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. Journal of Clinical Microbiology,
25:1868-1874, 1987.
56.
Brauner, A; Svenson, SB; Wretlind, B. Antibody response to lipid A and core oligosaccharide in patients
with bacteraemia. Serodiagnosis and Immunotherapy, 1:431-440, 1987.
57.
Jacobson, SH; Tullus, K; Wretlind, B; Brauner, A. Aerobactin mediated iron uptake by Escherichia coli
strains causing acute pyelonephritis and bacteraemia. Journal of Infection, 16:147-152, 1988.
58.
Strandvik, B; Malmborg, A-S; Bergan, T; Michalsen, H; Storrösten, OT; Wretlind, B.
Imipenem/cilastatin, an alternative treatment of Pseudomonas infection in cystic fibrosis. Journal of
Antimicrobial Chemotherapy, 21:471-480, 1988.
59.
Bally, M; Filloux, A; Murgier, M; Wretlind, B; Lazdunski, A. Cloning of xcp genes involved in protein
secretion in Pseudomonas aeruginosa. In NATO ASI Series. Vol H16 Membrane Biogenesis, pp. 439-444.
Edited by JAF Op den Kamp. Springer-Verlag, Berlin Heidelberg, 1988.
60.
Brauner, A; Svenson, SB; Wretlind, B. Immunological characterization of antibody responses to
Escherichia coli O antigens in bacteraemic patients. Serodiagnosis and Immunotherapy in Infectious Disease,
2:291-299, 1988.
61.
Karlsson, M; Möllegård, I; Stiernstedt, G; Henriksson, A; Wretlind, B. Characterization of antibody
response in patients with Borrelia meningitis. Serodiagnosis and Immunotherapy in Infectious Disease,
2:375-386, 1988.
62.
Granström, G; Wretlind, B; Salenstedt, C-R; Granström, M. Evaluation of serological assays for
diagnosis of whooping cough. Journal of Clinical Microbiology, 26:1018-1023, 1988.
63.
Granström, M; Wretlind, B; Markman, B; Cryz, S. Enzyme-linked immunosorbent assay to evaluate the
immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Journal of Clinical
Microbiology, 26:2257-2261, 1988.
64.
Filloux, A; Bally, M; Murgier, M; Wretlind, B; Lazdunski, A. Cloning of xcp genes located at the 55 min
region of the chromosome and involved in protein secretion in Pseudomonas aeruginosa. Molecular
Microbiology, 3:261-265, 1989.
65.
Brauner, A; Kaijser, B; Svenson, SB; Wretlind, B. Determination of antibody response in patients with
bacteraemia to eight Escherichia coli O antigens. Serodiagnosis and Immunotherapy in Infectious Disease,
3:65-73, 1989.
66.
Ostroff, RM; Wretlind, B; Vasil, ML. Mutations in the hemolytic phospholipase C operon result in
decreased virulence of Pseudomonas aeruginosa PAO1 grown under phosphate limiting conditions. Infection
and Immunity, 57:1369-1373, 1989.
67.
Brauner, A; Jacobson, SH; Kaijser, B; Svenson, SB; Wretlind, B. Serological responses to eight
Escherichia coli O antigens in female patients with acute pyelonephritis. Serodiagnosis and Immunotherapy
in Infectious Disease, 3:141- 148, 1989.
68.
Brauner, A; Jacobson, SH; Svenson, SB; Wretlind, B. Inhibition of antibody binding to homologous
Escherichia coli lipopolysaccharides with purified O antigen polysaccharides in sera from patients with acute
pyelonephritis. Serodiagnosis and Immunotherapy in Infectious Disease, 3:211-217, 1989
69.
Bally, M; Wretlind, B; Lazdunski, A. Protein secretion in Pseudomonas aeruginosa: Molecular cloning and
characterization of the xcp-1 gene. Journal of Bacteriology, 171:4342-4348, 1989.
70.
Hemlin, C; Brauner, A; Carenfelt, C; Wretlind, B. Nasopharyngeal culture with quantitative analysis of
pathogens in chronic otitis media with effusion. Effects on pathogen yield of different swabs and transport
methods. APMIS, 97:606-610, 1989
71.
Hemlin, C; Brauner, A; Carenfelt, C; Wretlind, B. Test-retest reliability of the nasopharyngeal culture in
children. APMIS, 97:887-890, 1989.
72.
Karlsson, M; Möllegård, I; Stiernstedt, G; Wretlind, B. Comparison of Western blot and enzyme-linked
immunosorbent assay for diagnosis of Lyme borreliosis. European Journal of Clinical Microbiology and
Infectious Diseases, 8:871-878, 1989.
73.
Lindgren, V; Ostroff, R; Vasil, ML; Wretlind, B. Genetic mapping of the structural gene for
phospholipase C in Pseudomonas aeruginosa PAO. Journal of Bacteriology, 172:1155-1156, 1990.
74.
Karlsson, M; Stiernstedt, G; Granström, M; Åsbrink, E; Wretlind, B. Comparison of flagellum and
sonicate antigens for serological diagnosis of Lyme borreliosis. European Journal of Clinical Microbiology
and Infectious Diseases, 9:169-177, 1990.
75.
Granström, G; Granström, M; Anderson, M; Lindquist, U; Leontein, K; Svenson, SB; Wretlind, B.
Bordetella pertussis lipopolysaccharide as antigen in ELISA for serological diagnosis of whooping cough.
Serodiagnosis and Immunotherapy in Infectious Disease, 4:151-158, 1990.
76.
Enocksson, E; Wretlind, B; Sterner, G; Anzén, B. Listeriosis during pregnancy and in neonates.
Scandinavian Journal of Infectious Diseases, Suppl. 71:89-94, 1990.
77.
Brauner, A; Hylander, B; Wretlind, B; Östenson, C-G; Kühn, I. Escherichia coli populations from
diabetic and non-diabetic patients with bacteraemia and faecal samples from healthy subjects - a comparative
study. Epidemiology and Infection, 105:533-540, 1990.
78.
Brauner, A; Cryz Jr, SJ; Granström, M; Wretlind, B. Serological responses to eight Klebsiella
pneumoniae capsular polysaccharide antigens in patients with bacteremia. Serodiagnosis and Immunotherapy
in Infectious Disease, 4:487-493, 1990.
79.
Swedish Study Group. A randomized multicenter trial of pefloxacin plus metronidazol versus gentamicin
plus metronidazol in the treatment of severe intraabdominal infections. Journal of Antimicrobial
Chemotherapy 26 Suppl. B:173-180, 1990.
80.
Granström, G; Wretlind, B; Granström, M. Diagnostic value of clinical and bacteriological findings in
pertussis. Journal of Infection, 22:17-26, 1991.
81.
Hemlin, C; Brauner, A; Carenfelt, C; Wretlind, B. Nasopharyngeal flora in otitis media with effusion. A
comparative semiquantitative analysis. Acta Otolaryngologica (Stockholm), 111:556-561, 1991.
82.
Brauner, A; Kaijser, B; Wretlind, B; Kühn, I. Characterization of Escherichia coli isolated in blood, urine
and faeces from bacteraemic patients and possible spread of infection. APMIS 99:381-386, 1991.
83.
Szanto, E; Granfors, K; Wretlind, B. Acute anterior uveitis, arthritides and enteric antigens. Clinical
Rheumatology, 10:395-400, 1991.
84.
Eriksson, M; Granström, G; Wretlind, B; Granström, M; Askelöf, P. Bordetella pertussis adenylate
cyclase activity in nasopharyngeal aspirates for rapid diagnosis of whooping cough in relation to culture and
serology. Scandinavian Journal of Infectious Diseases, 23:731-735, 1992.
85.
Wiström, J; Jertborn, M; Ekwall, E; Norlin, K; Söderquist, B; Strömberg, A; Lundholm, R; Hogevik,
H; Lagergren, L; Englund, G; Norrby, SR; The Swedish Study Group. Empiric treatment of acute
diarrheal disease with norfloxacin: a placebo-controlled study. Annals of Internal Medicine, 117:202-208,
1992.
86.
Wretlind, B; Strömberg, A; Östlund, L; Sjögren, E; Kaijser, B. Rapid emergence of quinolone resistance
in Campylobacter jejuni in patients treated with norfloxacin. Scandinavian Journal of Infectious Diseases,
24:685-686, 1992.
87.
Brismar, B; Malmborg, AS; Tunevall, G; Wretlind, B; Bergman, L; Mentzing, LO; Nyström, PO;
Kihlström, E; Bäckstrand, B; Skau, T; Kasholm-Tegve, B; Sjöberg, L; Olsson-Liljequist, B; Tally, FP;
Gatenbeck, L; Eklund, AE; Nord, CE.. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of
intraabdomonal infections. Antimicrobial Agents and Chemotherapy, 36:2766-2773, 1992.
88.
Bygdeman, SM; Rudén, A-K; Jonsson, A; Lidbrink, P; Olofsson, M-B; Bäckman, M; Gästrin, B;
Kallings, I; Ramberg, M; Rylander, M; Wretlind, B. Antibiotic susceptibility, serovars and auxotypes of
gonococcal isolates in Stockholm, Sweden. Relation to geographical origin of the infection. International
Journal of STD & AIDS, 4:33-40, 1993.
89.
Eklund, AE; Nord, CE; The Swedish Study Group. A randomized multicenter trial of
piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections.
Journal of Antimicrobial Chemotherapy, 31 Suppl. A: 79-85, 1993.
90.
Brauner, A; Cryz, SJ; Granström, M; Hanson, HS; Löfstrand, L; Strandvik, B; Wretlind, B.
Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients
with cystic fibrosis or bacteremia. European Journal of Clinical Microbiology and Infectious Diseases
12:430-436, 1993.
91.
Brauner, A; Hylander, B; Wretlind, B. Interleukin-6 and interleukin-8 in dialysate and serum from patients
on continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 22:430-435, 1993.
92.
Gårdlund, B; Sjölin, J; Nilsson, A; Roll, M; Wickerts, C-J; Wikström, B; Wretlind, B. Plasmapheresis
for the treatment of primary septic shock in humans. Scandinavian Journal of Infectious Diseases, 25:757761, 1993.
93.
Lutsar, I; Narska, M; Gontmacher, A; Wretlind, B. Cerebrospinal fluid IL-6 levels in children with and
without infections in the central nervous system. Pediatric Research 36, A59, 1994.
94.
Tullus, K; Fituri, O; Burman, LG; Wretlind, B; Brauner, A. Interleukin-6 and interleukin-8 in the urine
of children with pyelonephritis. Pediatric Nephrology, 8:280-284, 1994.
95.
Jacobson, SH; Hylander, B; Wretlind, B; Brauner, A. Interleukin-6 and interleukin-8 in serum and urine
in patients with acute pyelonephritis in relation to bacterial-virulence-associated traits and renal function.
Nephron, 67, 172-179, 1994.
96.
Tullus, K; Fituri, O; Linné, T; Escobar-Billing, R; Wikstad, I; Karlsson, A; Burman, LG; Wretlind, B;
Brauner, A. Urine interleukin-6 and interleukin-8 in children with acute pyelonephritis, in relation to DMSA
scintigraphy in the acute phase and at 1-year follow-up. Pediatric Radiology, 24, 513-515, 1994.
97.
The Swedish CDAD Study Group. Treatment of Clostridium difficile associated diarrhea and colitis with an
oral preparation of teicoplanin; a dose finding study. Scandinavian Journal of Infectious Diseases, 26:309316, 1994.
98.
Eriksson, S; Granström, L; Olander, B; Wretlind, B. Sensitivity of interleukin-6 and C-reactive protein
concentrations in the diagnosis of acute appendicitis. European Journal of Surgery, 161, 41-45, 1995.
99.
Günther, G; Gårdlund, B; Hast, R; Kimby, E; Nordin, M; Wretlind, B. Endotoxaemia and inflammatory
mediators in febrile patients with haematological disease. Journal of Internal Medicine, 237, 27-33, 1995
100.
Raqib, R; Lindberg, AA; Wretlind, B; Bardhan, PK; Andersson, U; Andersson, J. Persistence of local
cytokine production in shigellosis in acute and convalescent stages. Infection and Immunity, 63, 289-296,
1995.
101.
Raqib, R; Wretlind, B; Andersson, J; Lindberg, AA. Cytokine secretion in acute shigellosis is correlated
to disease activity and directed more to stool than to plasma. Journal of Infectious Diseases, 171, 376-384,
1995.
102.
Islam, D; Wretlind, B; Ryd, M; Lindberg, AA; Christensson, B. Immunoglobulin subclass distribution
and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infection and
Immunity, 63, 2054-2061, 1995.
103.
Gårdlund, B; Sjölin, J; Nilsson, A; Roll, M; Wickerts, C-J; Wretlind, B. Plasma levels of cytokines in
primary septic shock in humans: correlation with disease severity. Journal of Infectious Diseases, 172, 296301, 1995.
104.
Raqib, R; Lindberg, AA; Björk, L; Bardhan, PK; Wretlind, B; Andersson, U; Andersson, J. Downregulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and
transforming growth factor
Shigella infection.
Infection and Immunity, 63, 3079-3087, 1995.
105.
Örtqvist, Å; Hedlund, J; Wretlind, B; Carlström, A; Kalin, M. Diagnostic and prognostic value of
interleukin-6 and C-reactive protein in community acquired pneumonia. Scandinavian Journal of Infectious
Diseases, 27, 457-462, 1995.
106.
Minh, NB; Tram, LN; Trach, DD; Wretlind, B; Kärnell, A. Immune responses to Shigella
lipopolysaccharide and invasion plasmid antigens in Shigella infected Vietnamese patients. Serodiagnosis
and Immunotherapy in Infectious Diseases 8, 1-7, 1996.
107.
Tullus, K; Escobar-Billing, R; Fituri, O; Burman, LG; Karlsson, A; Wikstad, I; Wretlind, B; Brauner,
A. Interleukin-1
-1 receptor antagonist in the urine of children with acute pyelonephritis and
relation to renal scarring. Acta Paediatrica 85, 158-162, 1996.
108.
Brauner, A; Hylander, B; Wretlind, B. Tumor necrosis factor-1 receptor
antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. American
Journal of Kidney Diseases 27, 402-408, 1996.
109.
Tullus, K; Noack, GW; Burman, LG; Nilsson, R; Wretlind, B; Brauner, A. Elevated cytokine levels in
tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. European
Journal of Pediatrics 115, 112-116, 1996.
110.
Karlsson, M; Hammers, S; Nilsson-Ehle, I; Malmborg, A-S; Wretlind, B. Concentrations of doxycycline
and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrobial Agents
and Chemotherapy 40, 1104-1107, 1996.
111.
Islam, D; Wretlind, B; Lindberg, AA; Christensson, B. Changes in the peripheral blood T-cell V
repertoire in vivo and in vitro during shigellosis. Infection and Immunity 64, 1391-1399, 1996.
112.
Raqib, R; Ljungdahl, Å; Lindberg, AA; Wretlind, B; Andersson, U; Andersson, J. Dissociation between
cytokine mRNA expression and protein production in shigellosis. European Journal of Immunology 26,
1130-1138, 1996.
113.
Islam, D; Wretlind, B; Hammarström, L; Christensson, B; Lindberg, AA. Semiquantitative estimation of
Shigella antigen-specific antibodies: correlation with disease severity during shigellosis. APMIS 104: 563574, 1996.
114.
Lindkvist, P; Asrat, D; Nilsson, I; Tsega, E; Olsson, GL; Wretlind, B; Giesecke, J. Age at acquisition of
Helicobacter pylori infection: comparison of a high and a low prevalence country. Scandinavian Journal of
Infectious Diseases 28, 181-184, 1996.
115.
Hammers Stiernstedt, S; Wretlind, B. Dialysis culture more accurately determines the MIC of benzyl
penicillin for Borrelia burgdorferi. Antimicrobial Agents and Chemotherapy 40, 2882-2883, 1996.
116.
Cederholm, T; Wretlind, B; Hellström, K; Andersson, B; Engström, L; Brismar, K; Scheynius, A;
Forslid, J; Palmblad, J. Enhanced generation of interleukins 1 and 6 may contribute to the cachexia of
chronic disease. American Journal of Clinical Nutrition 65, 876-882, 1997.
117.
Khalil, A; Brauner, A; Bakhiet, M; Burman, LG; Jaremko, G; Wretlind, B; Tullus, K. Cytokine gene
expression during experimental Escherichia coli pyelonephritis in mice. Journal of Urology 158, 1576-1580,
1997.
118.
Diab, A; Zhu, J; Lindquist, L; Wretlind, B; Bakhiet, M; Link, H. Haemophilus influenzae and
Streptococcus pneumoniae induce different intracerebral mRNA cytokine patterns during the course of
experimental bacterial meningitis. Clinical and Experimental Immunology 109, 233-241, 1997.
119.
Diab, A; Zhu, J; Lindquist, L; Wretlind, B; Link, H; Bakhiet, M. Cytokine mRNA profiles during the
course of experimental Haemophilus influenzae bacterial meningitis. Clinical Immunology and
Immunopathology 85, 236-245, 1997.
120.
Sundström, J; Ågrup, C; Kronvall, G; Wretlind, B. Pseudomonas aeruginosa adherence to external
auditory canal epithelium. Archives of Otolaryngology – Head and Neck Surgery 123, 1287-1292, 1997.
121.
Minh, NB; Lanata, CF; Black, RE; Gil, AI; Kärnell, A; Wretlind, B. Age-related prevalence of Shigella
and Salmonella antibodies and their association to diarrhoeal diseases in Peruvian children. Scandinavian
Journal of Infectious Diseases, 30, 159-164, 1998.
122.
Gibreel, A; Sjögren, E; Kaijser, B; Wretlind, B; Sköld, O. Rapid emergence of high-level resistance to
quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC. Antimicrobial
Agents and Chemotherapy 42, 3276-3278, 1998.
123.
Jalal, S; Wretlind, B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
Microbial Drug Resistance, 4, 257-261, 1998.
124.
Amin, NE; Jalal, S; Wretlind, B. Alterations in GyrA and ParC associated with fluoroquinolone resistance
in Enterococcus faecium. Antimicrobial Agents and Chemotherapy, 43, 947-949, 1999.
125.
Stiernstedt, SH; Tadesse, T; Wretlind, B. Dialysis culture for determination of MIC and MBC of
benzylpenicillin against Borrelia burgdorferi. APMIS, 147, 380-382, 1999.
126.
Diab, A; Abdalla H, Li, HL; Shi, FD; Zhu, J; Höjberg, B; Lindquist, L; Wretlind, B; Bakhiet, M; Link,
H. Neutralization of MIP-2 and MIP-1 attenuates neutrophil recruitment in the central nervous system
during experimental bacterial meningitis. Infection and Immunity, 67, 2590-601, 1999.
127.
Jalal, S; Wretlind, G; Gotoh, N; Wretlind, B. Rapid identification of mutations in a multiple-drug efflux
pump in Pseudomonas aeruginosa. APMIS, 107, 1109-1116, 1999.
128.
Karpati, F; Hjelte, L; Wretlind, B. TNF- and IL-8 in consecutive sputum samples from cystic fibrosis
patients during antibiotic treatment. Scandinavian Journal of Infectious Diseases, 12, 75-79, 2000.
129.
Jalal, S; Ciofu, O; Høiby, N; Gotoh, N; Wretlind, B. Molecular mechanisms of fluoroquinolone resistance
in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial Agents and Chemotherapy,
44, 710-712, 2000.
130.
Gabriel, AS; Ahnve, S; Wretlind, B, Martinsson, A. IL-6 and IL-1 receptor antagonist in stable angina
pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. Journal of Internal Medicine,
248, 61-66, 2000.
131.
Zachrisson, K; Neopikhanov, V; Wretlind, B; Uribe, A. Mitogenic action of tumour necrosis factor-alpha
and interleukin-8 on explants of human duodenal mucosa. Cytokine, 15, 148-155, 2001.
132.
Amin, NE; Lund, B; Tjernlund, A; Lundberg, C; Jalakas, K; Wretlind, B. Mechanisms of resistance to
imipenem in imipenem-resistant, ampicillin-sensitive Enterococcus faecium. APMIS, 109, 791-796, 2001.
133.
Lindbäck, E; Rahman, M; Jalal, S; Wretlind, B. Mutations in gyrA, gyrB, parC, and parE in quinolone
resistant strains of Neisseria gonorrhoeae. APMIS, 110:651-657, 2002.
134.
Sullivan, Å; Wretlind, B; Nord, CE. Will triclosan in toothpaste select for resistant oral streptococci?
Clinical Microbiology and Infection, 9:306-310, 2003.
135.
Danin, J; Linder, L; Lundqvist, G; Wretlind, B. Cytokines in periradicular lesions – effect of linezolid
treatment. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 96:492-498,
2003.
136.
Oh, H; Stenhoff, J; Jalal, S; Wretlind, B. Role of efflux pumps and mutations in genes for topoisomerase II
and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microbial Drug Resistance, 9:323-328,
2003.
137.
Ilhendyane, N; Sparrelid, E; Wretlind, B; Remberger, M; Andersson, J; Ljungman, P; Ringdén, P;
Henriques Normark, B; Allen, U; Low, DE; Norrby-Teglund, A. Viridans streptococcal septicemia in
neutropenic patients: Role of pro-inflammatory cytokines. Bone Marrow Transplantation, 33:79-85, 2004.
138.
Sultan, Z; Nahar, S; Wretlind, B; Lindbäck, E; Rahman, M. Comparison of mismatch amplification
mutation assay with DNA sequencing for characterization of fluoroquinolone resistance in Neisseria
gonorrhoeae. Journal of Clinical Microbiology, 42: 591-594, 2004.
139.
Leoni V; Masterman T; Mousavi FS; Wretlind B; Wahlund LO; Diczfalusy U; Hillert J; Björkhem I.
Diagnostic use of cerebral and extracerebral oxysterols. Clinical Chemistry and Laboratory Medicine,
42:186-191, 2004.
140.
Islam, S; Jalal, S; Wretlind, B. Expression of MexXY efflux pump in amikacin-resistant isolates of
Pseudomonas aeruginosa. Clinical Microbiology and Infection, 10:877-883, 2004.
141.
Gabriel AS; Martinsson A; Wretlind B; Ahnve S. IL-6 levels in acute and post myocardial infarction: their
relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. European Journal of
Internal Medicine, 15:523-528, 2004.
142.
Kugelberg, E; Löfmark, S; Wretlind, B; Andersson, DI. Reduction of fitness burden of quinolone
resistance in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 55:22-30, 2005.
143.
Lindbäck, E; Gharizadeh, B; Ataker, F; Airell, Å; Jalal, S; Nyrén, P; Wretlind, B. DNA gyrase gene in
Neisseria gonorrhoeae as indicator for resistance to ciprofloxacin and species verification. International
Journal of STD & AIDS, 16:142-147, 2005.
144.
Airell, Å; Lindbäck, E; Ataker, F; Jalakas-Pörnull, K; Wretlind, B. Verification of clinical samples,
positive in AMPLICOR Neisseria gonorrhoeae PCR, by 16S rRNA and gyrA compared to culture.
International Journal of STD & AIDS, 16: 415-419, 2005.
145.
Lu Q; Björkhem I; Wretlind B; Diczfalusy U; Henriksson P; Freyschuss A. Effect of ascorbic acid on
microcirculation in patients with type 2 diabetes. A randomized, placebo-controlled, cross-over study.
Clinical Science, 108:507-513, 2005.
146.
Amin, NE; Giske, C; Jalal, S; Keijser, B; Kronvall, G; Wretlind, B. Carbapenem-resistance mechanisms
in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance
patterns observed in clinical isolates. APMIS, 113, 187-196, 2005.
147.
Giske, C; Borén, C; Wretlind, B; Kronvall, G. Meropenem susceptibility breakpoint for Pseudomonas
aeruginosa strains hyperproducing mexB mRNA. Clinical Microbiology and Infection, 11:662-669, 2005.
148.
Karpati, F; Meurling, L; Wretlind, B; Hjelte, L. Interleukin-8 in sputum from cystic fibrosis patients
during ibuprofen treatment. In: Progress in Cystic Fibrosis Research, Ed.; M. A. Harrison. Nova Science
Publishers, 171-183, 2005.
149.
Gharizadeh, B; Akhras, M; Unemo, M; Wretlind, B; Nyrén, P; Pourmand, N. Detection of gyrA
mutations associated with ciprofloxacin resistance in Neisseria gonorrhoeae by rapid and reliable, preprogrammed short DNA sequencing. International Journal of Antimicrobial Agents, 26:486-490, 2005.
150.
Lundbäck, D; Fredlund, H; Berglund, T; Wretlind, B; Unemo, M. Molecular epidemiology of Neisseria
gonorrhoeae – identification of the first Swedish transmission chain of an azithromycin resistant strain.
APMIS, 114:67-71, 2006.
151.
Källman, O; Lundberg, C; Wretlind, B; Örtqvist, Å. Gram-negative bacteria from patients seeking
medical advice after the tsunami catastrophe. Scandinavian Journal of Infectious Diseases: 38:448-450,
2006.
152.
Westling, K; Farra, A; Cars, B; Ekblom AG; Sandstedt, K; Settergren, B; Wretlind, B; Jorup, C. Cat
bite wound infections. A prospective clinical and microbiological study at three emergency wards in
Stockholm, Sweden. Journal of Infection, 53: 403-407, 2006.
153.
Lindbäck, E; Islam, S; Unemo, M, Lang, C; Wretlind, B. Transformation of ciprofloxacin resistant
Neisseria gonorrhoeae gyrA, parE and porB1b genes. International Journal of Antimicrobial Agents, 28:206211: 2006.
154.
Lindbäck, E; Unemo, M; Akhras, M; Gharizadeh, B; Fredlund H; Pourmand, N; Wretlind, B.
Pyrosequencing of the DNA gyrase gene in Neisseria species: Effective indicator of ciprofloxacin
susceptibility in Neisseria gonorrhoeae. APMIS, 114: 837-841, 2006.
155.
Westling, K; Julander, I; Ljungman, P; Nord CE; Wretlind, B. Viridans group streptococci in blood
culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin
resistance genes. International Journal of Antimicrobial Agents, 28: 292-296, 2006.
156.
Unemo, M; Sjöstrand, A; Akhras, M; Gharizadeh, B; Lindbäck, E; Pourmand, N; Wretlind, B;
Fredlund, H. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of
one ciprofloxacin resistant strain. APMIS, 2007: 115, 231-241.
157.
Cederholm, T; Persson, M; Andersson, P; Stenvinkel, P; Nordfors, L; Madden, J; Vedin, I; Wretlind,
B; Grimble, RF; Palmblad, J. Polymorphism in cytokine genes influence long-term survival differently in
elderly male and female patients. Journal of Internal Medicine, 2007, 262, 215-223.
158.
Berglund, T; Asikainen, T; Grutzmeier, S; Rudén, AK; Wretlind, B; Sandström, E. The epidemiology
of gonorrhea among men who have sex with men in Stockholm, Sweden. Sexually Transmitted Diseases,
2007, 34: 174-179.
159.
Nilsson, E; Amini, A; Wretlind, B; Larsson, A. Pseudomonas aeruginosa infections are prevented in cystic
fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. Journal of Chromatography
B, 2007, 856: 75-80.
160.
Özenci, V; Tegmark-Wisell, K; Lundberg, C; Wretlind, B. Rapid culture and identification: A practical
way of early preliminary laboratory diagnosis of sepsis. Clinical Microbiology and Infection, 2007, 14: 177180.
161.
Farra, A; Islam, S; Strålfors, A; Sörberg, M; Wretlind, B. Role of outer membrane protein OprD and
penicillin-binding proteins in Pseudomonas aeruginosa resistance to imipenem and meropenem. International
Journal of Antimicrobial Agents, 2008, 31: 427-433.
162.
Giske, CG; Buarø, L; Sundsfjord, A; Wretlind, B. Alterations of porin, pumps and penicillin-binding
proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa. Microbial Drug Resistance,
2008, 14: 23-30.
163.
Westling, K; Julander, I; Ljungman, P; Vondracek, M; Wretlind, B; Jalal, S. Identification of species of
viridans streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene rnpB.
Journal of Infection, 2008, 56: 204-210.
164.
Abd, H; Wretlind, B; Saeed, A; Idsund, E; Hultenby, K; Sandström G. Pseudomonas aeruginosa utilizes
its type III secretion system to kill the free-living amoeba Acanthamoeba castellani. Journal of Eukaryotic
Microbiology, 2008, 55:235-243.
165.
Källman, O; Motakefi, A; Wretlind, B; Kalin, M; Olsson-Liljequist, B; Giske, CG. Cefuroxime nonsusceptibility in multi-drug resistant Klebsiella pneumoniae overexpressing ramA and acrA and expressing
ompK35 at reduced levels. Journal of Antimicrobial Chemotherapy, 2008, 68: 986-990.
166.
Islam, S; Oh, H; Jalal, S; Karpati, F; Ciofu, O: Høiby, N; Wretlind, B. Chromosomal mechanisms of
aminoglycoside resistance mechanisms in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Clinical Microbiology and Infection, 2009, 15:60-66.
167.
Källman, O; Giske, CG; Samuelsen, Ø; Wretlind, B; Kalin, M; Olsson-Liljequist, B. Interplay of efflux,
impermeability and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL producing
isolates of Escherichia coli. Microbial Drug Resistance, 2009, 15:91-95.
168.
Sarker, P; Bhuiyan, TR; Qadri, F; Alam, NH; Wretlind, B; Bishop, A; Mathan, M; Agerberth, B;
Andersson, J; Raqib, R. Differential expression of enteric neuroimmune-network in invasive and acute
watery diarrhoea. Neurogastroenterology and Motility. 2010, 22: 70-78.
169.
Andrésen, C; Jalal, S; Aili, D; Wang, Y; Islam, S; Jarl, A; Liedberg, B; Wretlind, B; Mårtensson, L-G;
Sunnerhagen, M. Critical biophysical properties in the Pseudomonas aeruginosa efflux regulator MexR are
targeted by mutations conferring multi-drug resistance (MDR). Protein Science, 2010, 19: 680-692.
REVIEWS
1.
Wretlind, B; Pavlovskis, OR. The role of proteases and exotoxin A in the pathogenicity of Pseudomonas
aeruginosa infections. Scandinavian Journal of Infectious Diseases Suppl. 29:13-19, 1981.
2.
Pavlovskis, OR; Wretlind, B. Pseudomonas aeruginosa toxins. In: Medical Microbiology, vol. 1, pp. 97128. Edited by CSF Easmon and J Jeljaszewicz. Academic Press, New York, 1982.
3.
Pavlovskis, OR; Yaffe, LJ; Wretlind, B; Hedstrom, RC; Galloway, DR. Experimental Pseudomonas
aeruginosa burn infection. In: Pathophysiology of combined injury and trauma. Proceedings of the First
International Symposium, pp. 380-390. Edited by RI Walker, DF Gruber, TJ MacVittie, and JJ Conclin.
Armed Forces Radiobiology Research Institute, Bethesda, Maryland, 1983.
4.
Wretlind, B; Pavlovskis, OR. Pseudomonas aeruginosa elastase and its role in Pseudomonas infections.
Reviews of Infectious Diseases 5 Suppl:S998- S1004, 1983.
5.
Haas, D; Cryz, Jr., SJ; Itoh, Y; Leisinger, T; Lüthi, E; Mercenier, A; Reimmann, C; Rella, M; Soldati,
L; Watson, JM; Wretlind, B. Some applications of transposon insertion mutagenesis in Pseudomonas. In:
Génétique des micro-organisms industriels, pp. 91-111. Edited by H Heslot. Société Française de
Microbiologie, 1984.
6.
Wretlind, B; Pavlovskis, OR. Experimental Pseudomonas aeruginosa burn infection model in mice. In:
Experimental Models in Antimicrobial Chemotherapy, volume 2, pp. 147-154. Edited by O Zak and MA
Sande. Academic Press, London, 1986.
7.
Broberger, U; Herngren, L; Wretlind, B. A simplified model for the adjustment of gentamicin dosage in
newborn infants. In: Physiologic Foundations of Perinatal Care, vol. 2, pp. 270-275. Edited by L Stern, W
Oh, B Friis-Hansen. Elsevier, New York, 1987.
8.
Sköldenberg, BR; Stiernstedt, GT; Karlsson, M; Wretlind, B; Svenungsson, B. Treatment of Lyme
borreliosis with special emphasis to neurological disease. Annals of the New York Academy of Sciences,
539:317- 323, 1988.
9.
Karlsson, M; Möllegård, I; Sköldenberg, B; Stiernstedt, G; Åsbrink, E; Wretlind, B. Western blot
analysis of serum and cerebrospinal fluid antibodies to Borrelia strains in patients with Borrelia meningitis.
Annals of the New York Academy of Sciences, 539, 386-387, 1988.
10.
Wretlind, B; Johnson, RC; Hansen, K; Preac-Mursic, V. Antibiotic susceptibility of Borrelia burgdorferi
in vitro and in animal models. Scandinavian Journal of Infectious Diseases, Suppl. 77:143-144, 1991.
11.
Raqib, R; Wretlind, B; Lindberg, AA; Ljungdahl, Å; Andersson, J. Pathogenesis and immune responses
in shigellosis. Annals of the New York Academy of Sciences: Microbial Pathogenesis and Immune Response
II, vol. 797, 299-301, 1996.
12.
Jalal, S; Amin, NE; Gotoh, N; Wretlind, B. Mutations to quinolone resistance in Pseudomonas aeruginosa
and Enterococcus faecium. Drugs, 58 Suppl. 2:119-120, 1999.
13.
Amin, NE; Wretlind, B; Wenger, A; Brandt, V; Bille, J. Ampicillin-sensitive, imipenem-resistant strains
of Enterococcus faecium (Letter to the editor). Journal of Clinical Microbiology, 40, 738, 2002.
14.
Källman, O; Lundberg, C; Wretlind, B; Örtqvist, Å. Ovanliga bakteriefynd i sår hos tsunamipatienter.
Läkartidningen, 102, 3660-3662, 2005.
15.
Giske, C; Wretlind, B. Kinoloner bör inte ges i monoterapi vid infektioner av Pseudomonas aeruginosa
(debattartikel). Läkartidningen, 103, 1121-1122, 2006.
16.
Evengård, B; Juto, P: Seigneurin, J-M; Wretlind, B. Beyond culturing in microbiology. In European
Manual of Clinical Microbiology. 1st ed., p 49-58, ESCMID, 2012.
17.
Freilich, J; Färm, G; Emtestam, L: Wretlind, B. Utbrott av Pseudomonas follikulit. Läkartidiningen 109,
2028-2030, 2012.